Skip to main content

Table 3 Baseline characteristics

From: Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies

Study§ Age (years) Males (%) Diabetes type & duration (years) HbA1c (%) TC (mg/dL) LDL-C (mg/dL) HDL-C (mg/dL) Non-HDL-C (mg/dL) apoB (mg/dL) TG (mg/dL)
4D 66 54 T2DM 18 6.7 218 125 36 182 ~ 261
4S 59 81 ~    260 188 46 214 ~ 132
 diabetes substudy 60 78 ~    259 186 43 216 ~ 150
ACCORD-Lipid 62 69 T2DM 10 8.3 175 100 38 137 ~ 164
ADDITION-Europe 60.3 58 T2DM 0 7 214 133 46 168 ~ 146
AFCAPS/TexCAPS 58 85 T1DM; T2DM    221 150 37 184 ~ 158
AIM-HIGH 64 85 ~   6.7 146 74 35 111 83 168
AleCardio 60.8 73 T2DM 8.6 7.8 152 79 42 110 ~ 152
ALERT 50 66 ~    247 158 50 197 ~ 195
ALLHAT-LLT 66 51 T2DM    224 146 48 176 ~ 152
Alpha-Omega 69 78 ~    183 100 50 133 ~ 146
ASCOT-LLA 63 81 ~    212 131 50 162 ~ 150
 diabetes substudy 63.6 76 T2DM    205 128 46 159 ~ 168
ASPEN 61 66 T2DM 8 7.8 194 113 47 147 ~ 147
AURORA 64 62 ~    176 100 45 131 82 157
 diabetes substudy 65 66 ~    174 97 43 131 ~ 168
BIP 60 91 T2DM    212 148 35 177 ~ 145
CARDS 62 68 T2DM 8 7.9 207 117 54 153 117 173
CARE 59 86 ~    209 139 39 170 ~ 156
 diabetes substudy 61 80 ~    206 136 38 168 ~ 164
CDP (clofibrate)   100 ~    252 ~ ~ ~ ~ 183
CDP (niacin)   100 ~    253 ~ ~ ~ ~ 183
dal-OUTCOMES 60.2 81 ~    145 76 42 103 81 134
DIS 46 56 T2DM 0   218 ~ ~ ~ ~ 157
FIELD 62 63 T2DM 5 6.9 195 119 43 152 97 173
GISSI-Prevenzione 60 86 T2DM (79 %) T1DM (21 %)    229 152 46 183 ~ 166
GREACE   79 ~    264 193 39 225 ~ 159
 diabetes substudy 55 56 T2DM (92 %) T1DM (8 %) 10.5 7.5 271 189 35 236 ~ 221
HATS 53 87 ~    200 128 30 170 119 219
HHS 47 100 ~    270 189 47 223 ~ 175
 diabetes substudy 49 100 T2DM 4.5   292 200 46 246 ~ 214
HPS - MRC/BHF   75 ~    228 131 41 187 114 186
 diabetes substudy 62.1 70 T2DM (90 %) T1DM (10 %) 27 7 220 124 41 179 110 204
HPS2-THRIVE 64.9 82.7 ~    128 63 44 84 68 127
IDEAL 62 81 ~    197 122 46 151 119 151
ILLUMINATE 61.3 77.8 T2DM    157 80 49 108 73 127
JELIS 61 31.4 ~    275 181 59 216 ~ 153
LEADER 68 100 ~    218 131 46 172 ~ 213
LIPID 62 83 ~    218 150 36 182 133 142
LIPS 60 84 T2DM; T1DM    200 131 38 162 ~ 160
MEGA 58.3 32 ~    242 157 58 184 ~ 128
ORIGIN 63.5 65 T2DM 5.4   189 112 46 143 ~ 142
PERFORM 67.2 62.5 ~    ~ 93 ~ ~   
Post-CABG 61.7 92 ~    226 156 39 187 ~ 158
PREDIMED 67 43 ~    219 143 53 172 102 142
PROACTIVE 61.8 66 T2DM 9.5 8.1 199 114 45 154 ~ 198
PROFIT-J 85 65 T2DM 11.3 7.4 198 115 55 144 ~ 141
PROSPER 75 48 ~    220 147 50 170 ~ 133
RPS 63.9 61.5 ~   6.7 216 132 51 165 ~ 150
SHARP 62 63 ~    189 107 43 146 92 205
STABILITY 65 81 ~    ~ 80 45 ~   
STENO-2 54.9 74 T2DM 5.8 8.6 210 133 40 170 ~ 159
TNT 61 81 ~    175 97 47 128 111 151
 diabetes substudy 63 73 ~ 8.5 7.4 175 96 45 130 113 171
VA Cooperative Study 55 100 ~    244 ~ ~ ~ ~ ~
VA-HIT 64 100 ~    175 111 32 143 96 161
 diabetes substudy 65   ~    172 108 31 141 ~ 166
mean 61.7 74   7.5 7.49 209 126 44 161 99 162
standard deviation 6.4 17   4.9 0.68 34 32 7 32 19 27
  1. §: see legend to Table 1 for study acronyms definition; apoB: apolipoprotein B100; C: cholesterol; HbA1c: glycated haemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; T1DM and T2DM: type 1 and type 2 diabetes mellitus; TG: triglycerides
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840